Oncology Market Forecast to 2015 (TA225)

Brand Spending and Development Opportunities

&nsbp;

CLICK TO DOWNLOAD
Published 2010
606 Pages
1000+ Metrics
900+ Charts and Diagrams

Overview Companies Metrics

Chart the future of the global oncology market
Explore the fiercely competitive oncology market with the most comprehensive resource available. Augment or build your models with deep, meticulously researched data — and expand your understanding of different drugs, classes and sub-classes.
Equip your team with 119 brand profiles, all of which contain painstaking detail:
- Historical and projected sales from 2006-2015
- Current and projected approvals
- Critical clinical trials to watch
- Analysis that places each drug in context against key competitors and market events
- Patent, generics and litigation information
After scouring the profiles, gauge your resource levels: Brand spending data tracks real-world dollars for promotion, medical affairs, market access and more — information you won't find anywhere else.
Give your teams all the oncology market research they need to make critical product decisions!
Back to Top
Companies Included in Oncology Market Research
Profiled Oncology Portfolios
- Amgen
- AstraZeneca
- Bristol-Myers Squibb
- Celgene
- Eli Lilly (including ImClone)
- Genzyme
- GlaxoSmithKline
- Johnson & Johnson
- Merck (including Schering-Plough)
- Novartis
- Pfizer (including Wyeth)
- Roche (including Genentech)
- Sanofi-Aventis
All Companies Included in Report
- Abbott
- Abraxis
- Allos Therapeutics
- Amgen
- AnGes
- Antisoma
- Ariad
- ArQule
- Array BioPharma
- Astellas
- AstraZeneca
- Bayer
- Bioenvision
- Biovail
- Bristol-Myers Squibb
- Celgene
- Cephalon
- Chugai
- Cougar
- Daiichi Sankyo
- Dendreon
- Eisai
- Eli Lilly
- Enzon
- Epicept
- Exelixis
- GenMab
- Genzyme
- GlaxoSmithKline
- GTx
- Infinity
- Johnson & Johnson
- Medivation
- Merck
- Merck KGaA
- Millennium
- Myriad
- Nektar
- Novartis
- Oncothyreon
- Onyx
- OSI
- Pfizer
- PharmaMar
- Poniard
- Progenics
- Regeneron
- Roche
- Sanofi-Aventis
- Seattle Genetics
- Sigma Tau
- Taisho
- Transgene
- Vical
Back to Top
Oncology Market Metrics
Chapter 1: Analysis of Cancer Drugs by Classes (119 Drug Profiles)
Brand Information:
- Brand and generic name
- Drug class
- Delivery mechanism
- Line of treatment
- Materiality to company(ies) portfolio
- Summary of key approvals
Sales Data:
- Historical/current sales to 2006
- Forecasted sales to 2015
Brand Analysis:
- Competitive and strategic positioning (current and projected)
- Market opportunities and brand growth (current and projected)
- Key clinical trials to watch
- Current state of product development
- Patent, generic and litigation information
Chapter 2: Top Companies' Oncology Portfolios
- Current and projected (2015) ranking in oncology market
- Oncology revenues from 2006-2015
- Share of oncology market
- Analysis of competitive and strategic positioning
- Breakdown of strengths, growth areas and competition
- Comparison of revenue for oncology versus other therapeutic areas
- Pipeline development chart
- Analysis of key products
Chapter 3: Brand Spending Benchmarks
Analysis of Average Brand Spending by Budget Category
- Advertising and promotion
- Decision support
- Medical affairs
- Market access
Analysis of Average Brand Spending by Time Period:
- Pre-clinical to Phase 2
- Phase 3a
- Phase 3b
- First year on the market
Back to Top
Back to Top